ロード中...
RAD001 (Everolimus) Inhibits Growth of Prostate Cancer in the Bone and the Inhibitory Effects Are Increased by Combination With Docetaxel and Zoledronic Acid
INTRODUCTION: mTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3162313/ https://ncbi.nlm.nih.gov/pubmed/18361409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.20752 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|